What is prednisolone?

Prednisolone is a synthetic glucocorticoid. It acts in a similar way to cortisol, a steroid hormone produced by the adrenal glands, but it is prescribed at doses that produce a much stronger anti-inflammatory and immune-suppressing effect.

In the lungs, prednisolone can reduce inflammatory swelling, decrease immune-cell activity and suppress the release of inflammatory chemical signals. This can improve airflow, oxygen exchange and symptoms when inflammation is a major part of the disease.

Prednisolone does not treat every cause of breathlessness or every abnormality seen on a CT scan. It is not an antibiotic, does not directly treat pulmonary fibrosis and may worsen some untreated infections.

The clinical question matters

Before prescribing prednisolone, the clinician should identify what inflammatory process is being treated, how improvement will be measured and what will happen if the expected response does not occur.

Which lung diseases may be treated with prednisolone?

Acute asthma attacks

A short course may reduce airway inflammation, improve recovery and reduce the risk of relapse in a clinically significant exacerbation.

Severe eosinophilic asthma

Some patients require repeated rescue courses or maintenance oral corticosteroids, although specialist treatment aims to minimise this exposure.

COPD exacerbations

A short course may be prescribed during selected exacerbations to improve recovery, particularly when airflow obstruction and inflammation are significant.

Sarcoidosis

Prednisolone may be used when pulmonary or extrapulmonary inflammation is causing clinically important symptoms, organ dysfunction or progressive disease.

Organising pneumonia

Steroids can produce substantial improvement when the diagnosis is correct, but infection and other mimics must first be considered.

Hypersensitivity pneumonitis

Selected inflammatory cases may improve, particularly after removal of the triggering antigen. Long-term fibrotic disease may respond less well.

Connective-tissue-disease ILD

Corticosteroids may form part of treatment in selected inflammatory patterns, usually alongside or followed by a steroid-sparing strategy.

Eosinophilic lung disease

Prednisolone is often highly effective, but the cause of the eosinophilia and the risk of relapse require careful assessment.

Allergic bronchopulmonary aspergillosis

Oral corticosteroids may be used to control inflammatory exacerbations, often with antifungal or biological treatment considered in selected patients.

Pulmonary vasculitis

High-dose corticosteroids may be needed as part of urgent specialist treatment, usually with additional immunosuppression.

Prednisolone is not suitable for every interstitial lung disease

Interstitial lung disease is a broad group of disorders. Some are predominantly inflammatory and may respond to corticosteroids. Others are predominantly fibrotic and require a different treatment strategy.

Prednisolone in asthma

Asthma involves variable airway narrowing and inflammation. Inhaled corticosteroids are the foundation of long-term anti-inflammatory treatment because they deliver medicine directly to the airways with less systemic exposure.

Prednisolone is generally reserved for an acute attack or for a small number of people with severe asthma who remain dependent on oral corticosteroids despite optimised inhaled and specialist treatment.

A rescue course may be appropriate when asthma control deteriorates significantly.

Increasing breathlessness or wheeze
Reduced peak flow
Night waking and reliever overuse
Poor response to usual inhaled treatment
Clinically significant exacerbation

Maintenance prednisolone should trigger specialist review and an active steroid-reduction strategy.

Confirm the diagnosis
Review inhaler technique and adherence
Treat rhinitis, reflux and other comorbidities
Assess eosinophils and allergic phenotype
Consider biological therapy

Repeated rescue courses are not harmless

Even when each course is short, cumulative exposure can increase the risk of diabetes, osteoporosis, cataracts, infection, cardiovascular complications and adrenal suppression. Frequent courses should prompt an asthma-control and severe-asthma review.

Prednisolone in inflammatory interstitial lung disease

Interstitial lung diseases affect the supporting tissue and airspaces of the lungs. The balance between active inflammation and irreversible fibrosis differs considerably between conditions.

Prednisolone is most likely to help when inflammation is a major driver and when there is a realistic possibility of improving symptoms, lung function, oxygenation or CT abnormalities.

Condition or pattern	Possible role of prednisolone	Important considerations
Pulmonary sarcoidosis	May reduce active granulomatous inflammation and improve symptoms or organ function	Not every radiographic abnormality requires treatment
Organising pneumonia	Often produces a clinically meaningful response	Infection, malignancy, drug reactions and autoimmune disease may mimic or cause the pattern
Inflammatory connective-tissue-disease ILD	May form part of initial control	Choice depends on disease type; systemic sclerosis requires particular caution with higher steroid doses
Cellular hypersensitivity pneumonitis	May improve active inflammation after antigen avoidance	Fibrotic disease may respond incompletely
Idiopathic pulmonary fibrosis	Not used as routine long-term disease-modifying treatment	Antifibrotic treatment and supportive management are more relevant
Progressive pulmonary fibrosis	Depends on whether active inflammation remains present	Antifibrotic therapy may be considered in selected progressive fibrotic disease

Response should be measured

Symptoms alone may be unreliable. Treatment response may require lung-function testing, oxygen assessment, exercise testing, blood markers and repeat imaging at an appropriate interval.

Side effects of prednisolone

The likelihood of side effects generally increases with the dose, treatment duration, cumulative exposure, age, existing medical conditions and use of other corticosteroids.

Increased appetite and weight gain

Facial rounding and altered fat distribution

Fluid retention and ankle swelling

Raised blood glucose or steroid-induced diabetes

Increased blood pressure

Osteoporosis and fragility fractures

Muscle weakness and loss of muscle mass

Increased susceptibility to infection

Bruising and thinning of the skin

Cataracts and raised eye pressure

Insomnia, anxiety or mood changes

Adrenal suppression and steroid withdrawal

Psychological effects can be significant

Some people experience irritability, agitation, anxiety, low mood, insomnia or unusually elevated mood. Rarely, severe depression, mania, confusion or psychosis may occur and requires urgent medical review.

Short courses versus long-term prednisolone

Treatment pattern	Typical purpose	Main concerns
Single short course	Acute asthma or COPD exacerbation	Sleep disturbance, mood effects, glucose rise, stomach symptoms and temporary infection risk
Repeated short courses	Recurrent exacerbations	Increasing cumulative toxicity and possible adrenal suppression
Several weeks or months	Inflammatory ILD or systemic inflammatory disease	Bone loss, diabetes, infection, muscle weakness and need for tapering
Long-term maintenance	Severe steroid-dependent inflammatory disease	High cumulative toxicity and need for steroid-sparing treatment

Adrenal suppression and stopping prednisolone safely

The adrenal glands normally make cortisol. When prednisolone is taken for long enough, the brain and adrenal glands reduce natural cortisol production because the body detects an external steroid supply.

A brief rescue course can often be stopped at the end of the prescribed course. Longer courses, repeated courses and combined exposure from oral, inhaled, nasal, injected or topical steroids can increase the risk of adrenal suppression.

Do not stop long-term prednisolone suddenly

Abrupt withdrawal can cause steroid-withdrawal symptoms or adrenal insufficiency. Possible symptoms include:

Severe fatigue or weakness
Dizziness or low blood pressure
Nausea, vomiting or abdominal pain
Muscle and joint pain
Headache
Loss of appetite
Worsening of the underlying lung disease

Steroid emergency information

Some patients with current or possible adrenal suppression need a steroid emergency card and sick-day instructions for severe infection, surgery, trauma or vomiting. This should be discussed with the prescribing team.

How clinicians reduce the risks of prednisolone

Confirm the indication Establish that inflammation is likely to respond and exclude important infections or alternative diagnoses.
Use an appropriate starting dose The dose should reflect disease severity and should not be higher than necessary.
Set a review point Decide when symptoms, lung function, blood tests or imaging will be reassessed.
Reduce exposure when control improves Use a supervised taper when treatment duration or adrenal risk requires it.
Monitor preventable complications Review blood pressure, weight, glucose, infection, eyes, muscles and bone risk.
Introduce steroid-sparing treatment Consider biologics, inhaled treatment, immunomodulators or other disease-specific therapy.

Protecting bone health

Systemic corticosteroids can reduce bone formation, increase bone breakdown, weaken muscles and increase falls. Fracture risk can rise before a large change is visible on a bone-density scan.

Fracture-risk assessment

Age, previous fractures, steroid dose, treatment duration, menopause, smoking, alcohol use, body weight and other conditions should be reviewed.

DXA scanning

Bone-density measurement and vertebral assessment may be appropriate when prolonged systemic treatment is expected.

Calcium and vitamin D

Intake and vitamin-D status should be adequate, but supplements should be targeted to diet, blood results, kidney function and individual risk.

Bone-protective medicine

Bisphosphonates or another osteoporosis treatment may be needed when fracture risk is sufficiently high.

Resistance and weight-bearing exercise

Appropriate activity supports bone strength, muscle mass, balance and respiratory rehabilitation.

Falls prevention

Vision, balance, muscle weakness, footwear and the home environment may require review.

Infection risk and preventive care

Prednisolone can reduce immune responses and mask typical signs of infection. The risk is influenced by dose, duration, age, comorbidities and additional immune-suppressing medicines.

Vaccination review

Influenza, COVID-19, pneumococcal, shingles and other vaccines may be relevant according to age, immune status and treatment.

Pneumocystis prophylaxis

Preventive treatment may be considered when corticosteroids are combined with other important PJP risk factors. It is not routinely needed for every steroid course.

Tuberculosis and hepatitis screening

Screening may be appropriate before selected immunosuppressive or biological treatments.

Early assessment of infection

Fever, new cough, sputum, urinary symptoms, shingles or unusual skin inflammation should be reported promptly.

Do not rely on antibiotics to make prednisolone safe

Preventive antibiotics are used only for defined risks. They do not prevent all bacterial, viral or fungal infections and can cause adverse effects and antimicrobial resistance.

Does everyone need a proton-pump inhibitor?

Prednisolone can cause indigestion, but corticosteroid treatment alone does not automatically mean that every patient needs long-term acid-suppression treatment.

A proton-pump inhibitor may be appropriate when there is a separate gastrointestinal indication or additional ulcer risk, such as a previous ulcer, anticoagulant treatment or combined use of a non-steroidal anti-inflammatory medicine.

PPIs also require review

Long-term acid suppression can have its own adverse effects. Treatment should be prescribed for a defined indication and reviewed rather than continued indefinitely without reassessment.

Alternatives and steroid-sparing treatments

Treatment strategy	Possible use	Important limitations
Optimised inhaled corticosteroid treatment	Asthma and selected COPD patients	Inhaler choice, technique, adherence and dose require review
Asthma biologics	Severe eosinophilic, allergic or type-2 asthma and selected broader severe-asthma phenotypes	Eligibility depends on phenotype, exacerbations, biomarkers and prior treatment
Mycophenolate mofetil	Selected connective-tissue-disease ILD and inflammatory ILD	Requires blood monitoring and infection counselling
Azathioprine	Selected inflammatory lung and systemic conditions	Not suitable for every ILD; requires enzyme assessment and blood monitoring
Rituximab or other biological immunotherapy	Selected autoimmune ILD or vasculitis	Significant infection and infusion-related considerations
Cyclophosphamide	Severe or organ-threatening inflammatory disease	Substantial toxicity limits duration and requires specialist supervision
Nintedanib	Idiopathic pulmonary fibrosis and selected progressive fibrotic ILD	Slows progression rather than reversing established fibrosis
Pirfenidone	Idiopathic pulmonary fibrosis	Requires monitoring for gastrointestinal, skin and liver adverse effects
Antigen avoidance	Hypersensitivity pneumonitis	The relevant exposure can be difficult to identify
Pulmonary rehabilitation	Breathlessness, muscle weakness and reduced exercise capacity	Supports function but does not replace disease-specific treatment

Biological treatment for severe asthma

Biological treatments target specific inflammatory pathways rather than suppressing the entire immune system in the broad way that oral prednisolone does.

Omalizumab

Targets IgE and may be considered in appropriately selected allergic asthma.

Mepolizumab

Targets interleukin-5 and can reduce exacerbations in severe eosinophilic asthma.

Benralizumab

Targets the interleukin-5 receptor and produces marked eosinophil depletion.

Dupilumab

Targets signalling through interleukin-4 and interleukin-13 pathways in type-2 inflammatory disease.

Tezepelumab

Targets thymic stromal lymphopoietin and may be suitable across a broader range of severe-asthma phenotypes.

Treatment review

Response is assessed using exacerbations, symptoms, oral-steroid exposure, lung function and quality of life.

Biologics are not simply interchangeable

Selection depends on eosinophils, allergy, FeNO, comorbid nasal polyps, previous exacerbations, oral-steroid exposure and the person’s broader clinical phenotype.

Monitoring during prolonged prednisolone treatment

Weight and blood pressure

Fluid retention, appetite changes and metabolic effects should be identified early.

Blood glucose

Monitoring may include fasting glucose, HbA1c or more frequent testing in people with diabetes.

Bone and fracture risk

DXA, vertebral assessment and bone-protective treatment may be needed.

Eyes

Cataract and glaucoma assessment may be appropriate during long-term exposure or when visual symptoms develop.

Muscle strength

Proximal weakness may make stairs, rising from a chair and walking more difficult.

Infection and vaccination

Preventive care and new symptoms should be reviewed at regular intervals.

Mood and sleep

Changes may be overlooked unless discussed directly.

Adrenal suppression

Tapering, cortisol testing or endocrine assessment may be necessary in selected patients.

Practical advice for patients taking prednisolone

Take it exactly as prescribed

Do not alter the dose based only on how you feel unless you are following a clinician-approved action plan.

Take morning doses when advised

Morning administration may reduce sleep disruption and more closely follow the body’s natural cortisol rhythm.

Take it with food

This may reduce dyspepsia, although it does not remove all gastrointestinal risk.

Carry steroid information

Long-term users may require a steroid treatment or emergency card.

Report infection promptly

Do not wait for a high fever, because steroids can reduce the usual inflammatory response.

Keep a treatment record

Recording rescue courses helps clinicians assess cumulative exposure.

When urgent medical help is needed

Seek urgent assessment for serious symptoms

Severe or rapidly worsening breathlessness
Collapse, confusion or very low blood pressure
Persistent vomiting while dependent on steroids
High fever or severe infection during immunosuppression
Severe weakness after reducing or missing steroid doses
Black stools, vomiting blood or severe abdominal pain
Severe agitation, suicidal thoughts, mania or psychosis
New visual loss or severe eye pain

Call 999 for severe breathing difficulty, collapse, suspected adrenal crisis, severe mental-health disturbance or another immediately life-threatening symptom.

Conclusion

Prednisolone is a powerful and sometimes lifesaving treatment for acute asthma and selected inflammatory lung diseases.

Its benefit depends on using it for the correct diagnosis. It is not an appropriate routine treatment for every interstitial lung disease or every abnormal CT finding.

Short courses can still cause temporary effects, while repeated or prolonged treatment increases the risk of diabetes, osteoporosis, infection, muscle weakness, eye disease, mood disturbance and adrenal suppression.

Long-term treatment should use a structured monitoring plan, fracture-risk assessment, vaccination review and active consideration of steroid-sparing treatment.

In asthma, optimised inhaled treatment and biological therapies can reduce reliance on systemic corticosteroids. In inflammatory ILD, mycophenolate, azathioprine, rituximab or other immune-modifying treatment may be appropriate. Fibrotic ILD may require antifibrotic therapy rather than additional prednisolone.

Never stop prolonged prednisolone abruptly. Dose reduction should follow an individual plan that protects both adrenal function and control of the underlying lung disease.

Frequently asked questions

Is prednisolone the same as an anabolic steroid?

No. Prednisolone is a corticosteroid used to suppress inflammation. It is different from anabolic steroids used to increase muscle growth.

Can prednisolone help asthma?

Yes. A short course can be important during a significant asthma exacerbation. Long-term asthma control should rely primarily on optimised inhaled and specialist treatment.

Does prednisolone treat pulmonary fibrosis?

It may help inflammatory components of selected ILDs but does not reverse established fibrosis. Idiopathic pulmonary fibrosis is not routinely treated with long-term prednisolone.

Can I stop a five-day course suddenly?

A single brief rescue course can often be stopped at the end of the prescribed period. Follow the exact instructions provided, particularly when courses have been frequent or there is other steroid exposure.

Why must long-term prednisolone be reduced gradually?

Prolonged treatment can suppress natural cortisol production. A gradual reduction allows adrenal function to recover and helps detect recurrence of the underlying disease.

Will prednisolone cause weight gain?

It can increase appetite, fluid retention and alter fat distribution. Risk is greater with higher doses and longer courses.

Does everyone need calcium and vitamin D?

Adequate intake is important, but supplementation should be based on diet, vitamin-D status, kidney function and fracture risk. Some patients also need specific osteoporosis treatment.

Does everyone need a stomach-protection tablet?

No. A proton-pump inhibitor may be appropriate when there is a separate indication or additional ulcer risk, but it should not be prescribed automatically to every patient.

Can prednisolone increase infection risk?

Yes. The risk depends on dose, duration, age, underlying disease and other immunosuppressive treatments.

Do I need antibiotics while taking prednisolone?

Not routinely. Preventive antibiotics are reserved for defined risks, such as selected patients at increased risk of Pneumocystis pneumonia.

Can biologics replace prednisolone in severe asthma?

In appropriately selected patients, biologics can reduce exacerbations and oral-steroid exposure. They do not replace every rescue course and require specialist eligibility assessment.

References and further information

National Institute for Health and Care Excellence. Asthma: diagnosis, monitoring and chronic asthma management. View NICE asthma guidance
National Institute for Health and Care Excellence. Tezepelumab for treating severe asthma. View NICE technology appraisal
University Hospitals Plymouth NHS Trust. Severe asthma: prednisolone and adrenal insufficiency. View patient information
American College of Rheumatology. Guideline for prevention and treatment of glucocorticoid-induced osteoporosis. View guideline information
European Respiratory Society and European Alliance of Associations for Rheumatology. Clinical practice guidelines for connective-tissue-disease associated interstitial lung disease. View ERS/EULAR guidance

Prednisolone for Lung Disease: Benefits, Side Effects, and Alternatives.

Use the lowest effective exposure

Never change long-term treatment abruptly